FDA Approved: DIVALPROEX SODIUM — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved BluePoint Laboratories' supplemental application for Divalproex Sodium under ANDA078239, granting approval of a generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy
• Migraine

Drugs mentioned

• DIVALPROEX SODIUM (divalproex sodium)

Snippet

SUPPL AP for DIVALPROEX SODIUM (DIVALPROEX SODIUM)